European Pharmaceuticals
Alternatives
Geoffrey C. Hsu, partner of OrbiMed and manager of the BiotechGrowth trust, assesses the key drivers for the sector in 2016 and beyond.
08 November 2015
•
4 min read
Investment
The era of 'Big Pharma' is over and companies are transitioning to more complex biological products, explains Tim Crockford from Hermes Sourcecap.
11 June 2014
•
